- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04901884
심폐 기능 장애 평가를 위한 PET/MR 전후 방사선 치료
방사선 치료 후 일시적 또는 영구적인 심폐 기능 장애가 발생하는 환자를 식별하는 데 가능한 예후 지표로서 동시 심장 PET/MR, 대사 마커 및 순환 DNA의 탐색적 평가
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.
PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).
Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.
To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
연구 개요
상세 설명
RT is a well-known and established therapy or adjuvant therapy for the treatment of thoracic malignancies (breast cancer, lung cancer, lymphoma and others). It usually uses high energy radiation from x-rays, gamma rays or other charged particles to induce DNA damage in malignant cells. Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, the signs and symptoms of radiation induced cardiopulmonary dysfunction (RICPD) still persist. However, in the majority of cases, it remains unclear which cardiopulmonary damage is the main /leading cause for the clinical symptoms the patients are experiencing.
Hybrid PET/MRI is a promising technique that allows for truly simultaneous molecular, anatomic and functional imaging of the cardiopulmonary system. The simultaneity is an important aspect in this proposed study since only parameters measured at the same time in PET and MR can be used for an integrated, multimodality parameter for possible detection and prognostication of the different underlying processes of cardiopulmonary dysfunction after RT. Furthermore, certain PET-uptake of the RV have to be corrected for RV mass which is only possible with concomitant anatomical imaging. MR imaging and PET at different time point are not accurately reflective of the underlying pathophysiological pathways and metabolic state at the specific time points pre- and post radiotherapy. To our knowledge, there are no online publications of its use in the diagnosis and prognostication of cardiopulmonary dysfunction after RT and specifically PH.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Patrick Veit-Haibach, MD
- 전화번호: 6085 416-340-4800
- 이메일: Patrick.Veit-Haibach@uhn.ca
연구 연락처 백업
- 이름: Andrew Hope, MD
- 전화번호: 416-946-2124
- 이메일: Andrew.Hope@rmp.uhn.ca
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 2M9
- 모병
- University Health Network
-
연락하다:
- Patrick Veit-Haibach
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years
- Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy
- Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.
- A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age.
- Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).
Exclusion Criteria:
- Contraindication for MR as per current institutional guidelines.
- Contraindication for Gadolinium injection as per current institutional guidelines.
- Inability to lie supine for at least 45 minutes.
- Any patient who is pregnant or breastfeeding.
- Any patient with known hypersensitivity to 18F-FDG.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: One arm / exploratory study
Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours. |
(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change of FDG uptake of heart
기간: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of the left and right ventricles of heart will be measured and compared in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of FDG uptake of lungs
기간: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of left and right ratios within the lungs in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the heart function
기간: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
MRI of ventricular volumes in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the lung perfusion
기간: before radiotherapy and up to 16 weeks after completion of radiotherapy
|
Percentage of the perfused/ventilated lung segments will be evaluated and compared pre and post therapy by SPECT scans |
before radiotherapy and up to 16 weeks after completion of radiotherapy
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Patrick Veit-Haibach, MD, University Health Network, Toronto
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .